Neuropsychiatric Disorders and Epigenetics, Second Edition is a comprehensive reference on the epigenetic basis of common neuropsychiatric disorders. The volume is organized into chapters covering individual neuropsychiatric disorders, from addiction to anxiety and autism spectrum disorders, and is contributed by leading experts in their respective fields. The epigenetic aspects of each disorder are discussed in the context of the full range of associated epigenetic mechanisms, including DNA modification, histone post-translational modification, chromatin organization, and non-coding RNA. A particular emphasis is placed on potential epigenetic interventions when the effects of environmental stimuli on epigenetic states is particularly relevant to disease. This new edition has been fully updated to reflect recent research advances enabled by genomic technologies, as well as therapeutic interventions for previously unmanageable disorders. Several new chapters have been added on disorders or approaches not considered in the earlier edition, including epigenetics and anxiety disorders, epigenetics and neuroimaging in neuropsychiatric disorders, genome-wide approaches to epigenetic research, and the epigenetics of spinal muscular atrophy.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Section I. Neuropsychiatric Disorders and Epigenetics: General Aspects1. Introduction to Neuropsychiatric Disorders and Epigenetics
2. Environmental Factors and Epigenetics of Neuropsychiatric Disorders
3. Epigenetic Biomarkers in Neuropsychiatric Disorders
4. Epigenetics and Neuroimaging in Neuropsychiatric Disorders
5. Recent advances in genome-wide approaches to biomedical research
6. Single Cell Epigenomic Approaches in Neuropsychiatric Disorders
7. Neuropsychiatric Disorders and Epigenetics: Computational Approaches; Sampling methods; and Power analyses
Section II: Epigenetics of Neuropsychiatric Disorders
8. Epigenetics and Cognitive Disorders -Translational Aspects
9. Epigenetics in Autism Spectrum Disorders Translational Aspects
10. Epigenetic causes of intellectual disability the fragile X syndrome paradigm
11. Epigenetics of Attention-Deficit Hyperactivity Disorder
12. The epigenetics of brain aging and psychiatric disorders
13. Epigenetic therapy may alleviate cognitive deficits in Down syndrome by downregulating overexpressed chromosome 21 gene products
14. Epigenetics and Multiple Sclerosis
15. Epigenetics and Migraine
16. The role of epigenetics in the pathophysiology of epilepsy
17. Epigenetic Dysregulation in Brain Tumors and Neurodevelopment
18. Epigenetics and Cerebrovascular Diseases
19. Epigenetics of Spinal Muscular Atrophy and the Potential Role of Epigenetics in the Treatment of this Disorder
20. Epigenetics and Anxiety Disorders
21. Epigenetics and Eating Disorders
22. Epigenetics in Obesity
23. Epigenetics and Drug Addiction-Translational Aspects
24. Epigenetics and Alcohol Use Disorders
Section III: Summary and Outlook
25. Summary and Outlook
Authors
Jacob Peedicayil Professor, Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, India. Dr Jacob Peedicayil completed MBBS in 1984 and MD in pharmacology in 1991, both at the Christian Medical College, Vellore, India. From 1993 to 1995 he did a Post-Doctoral Fellowship at the Centre for Cellular and Molecular Biology, Hyderabad, India. From 1995 to 1998 he worked as a Research Fellow in the Department of Neurological Sciences, Christian Medical College, Vellore. Since 1998 he has been on the faculty of the Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, becoming a professor in 2007. He does theoretical research on epigenetics, focusing on epigenetics in psychiatry. In addition, he is involved in experimental research in smooth muscle pharmacology. Dennis R. Grayson Professor of Molecular Neuroscience, University of Illinois at Chicago, IL, USA. Dr Dennis R. Grayson received his PhD from the Department of Biochemistry at Wayne State University School of Medicine in 1984. He has been interested in mechanisms associated with gene expression for over 35 years. He joined the laboratory of Dr James E. Darnell at the Rockefeller University as a Post-Doctoral Fellow in 1984 to study cell-type specific transcription factors and their interaction with promoters and enhancers. In 1988, Dr Grayson joined the Fidia-Georgetown Institute for the Neurosciences at Georgetown University to study gene expression programs in neurons and continued this research program at Allegheny Singer Research Institutein Pittsburgh from 1995 to 1998. He continued his interests in psychiatry and joined the Psychiatric Institute at the University of Illinois in 1998. This represented a unique opportunity to pursue the molecular underpinnings of schizophrenia. Dr Grayson has received NRSA post-doctoral support, and R01 and K04 funding from the National Institutes of Health to support his work. He has published over 140 papers in peer-reviewed journals and is regularly invited to speak at numerous national and international meetings. He is currently Director of the Epigenetic Core of the Center for Alcohol Research in Epigenetics.
